Inhibitory effect of recombinant endostatin on angiogenesis and tumor growth of hepatoma.
- Author:
Peiyuan LI
1
;
Zuohua FENG
;
Guimei ZHANG
;
Hui ZHANG
;
Shengli XUE
;
Bo HUANG
;
Jusheng LIN
Author Information
1. Institute of Liver Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030.
- Publication Type:Journal Article
- MeSH:
Angiogenesis Inhibitors;
pharmacology;
Animals;
Antineoplastic Agents;
pharmacology;
Endostatins;
biosynthesis;
genetics;
pharmacology;
Escherichia coli;
genetics;
Liver Neoplasms, Experimental;
blood supply;
pathology;
Male;
Mice;
Neoplasm Transplantation;
Recombinant Proteins;
biosynthesis;
genetics;
pharmacology
- From:
Journal of Huazhong University of Science and Technology (Medical Sciences)
2003;23(3):223-226
- CountryChina
- Language:English
-
Abstract:
To study the influence of recombinant endostatin on angiogenesis and tumor growth of mice H22 hepatoma, tumor models were constructed by injecting H22 hepatoma cells into the leg muscle of mice. Recombinant endostatin was produced by gene engineering in E. coli. The recombinant protein was injected subcutaneously to treat transplanted hepatoma faraway. The weight of tumors was measured, and the changes of necrosis of tumor cells and vessel density were observed by immunohistochemistry. The results suggested that the growth of hepatoma models transplanted in the muscle of legs was suppressed by recombinant endostatin. The density of vascularity was decreased, but the necrosis of tumor cells increased. The inhibitory effect of recombinant endostatin on angiogenesis and tumor growth of hepatoma was not affected after chemotherapy.
